Clinical Trials Logo

Metabolic Diseases clinical trials

View clinical trials related to Metabolic Diseases.

Filter by:

NCT ID: NCT02853734 Recruiting - Obesity Clinical Trials

Inflammatory Status of Visceral Adipose Tissue in Obese Patients Related to Periodontitis Severity

BACTERIOB
Start date: March 12, 2019
Phase: N/A
Study type: Interventional

The research aims to compare the inflammatory status of visceral adipose tissue from obese patients depending on the presence and severity of periodontitis, in order to establish a potential causal link between the severity of the bacterial contamination and insulin resistance.

NCT ID: NCT02847351 Active, not recruiting - Clinical trials for Nutritional and Metabolic Diseases

A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects.

Start date: July 2014
Phase: N/A
Study type: Interventional

The study aimed to investigate whether an Arabinoxylan-enriched crackers consumption for 4 weeks in overweight and obese patients without diabetes mellitus have specific healthy effects on glycemic control (reduction of homeostatic model assessment -HOMA index-). Furthermore, study evaluated the effects of Arabinoxylan on insulin, lipid and Ghrelin.

NCT ID: NCT02845622 Completed - Clinical trials for Cardiovascular Diseases

Effects of Hazelnuts and Cocoa on Metabolic Parameters and Vascular Reactivity

Start date: June 2014
Phase: N/A
Study type: Interventional

This study aims to assess the effects of hazelnuts, cocoa, and the combination of both on vascular reactivity and metabolic profile. Participants, divided in six groups, will receive one of these breakfast integrations for 14 days: group 1) 30 g peeled hazelnuts; group 2) 30 g unpeeled hazelnuts; group 3) snack with 30 g peeled hazelnuts; group 4) snack with 2.5 g cocoa powder; group 5) snack with 30 g peeled hazelnuts and 2.5 g cocoa; group 6) empty snack, control group.

NCT ID: NCT02830763 Terminated - Clinical trials for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV)

Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

Start date: September 5, 2016
Phase: N/A
Study type: Interventional

This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules (food-grade CNT-02) in subjects with primary triglyceride deposit cardiomyovasculopathy (TGCV) and neutral lipid storage disease with myopathy (NLSD-M) associated with adipose triglyceride lipase (ATGL) genetic defects.

NCT ID: NCT02809664 Recruiting - Heart Diseases Clinical Trials

Feasibility and Safety of Ultrasound Guided Installation Central Subclavian Catheter Through Supraclavicular Way

Start date: October 14, 2015
Phase: N/A
Study type: Observational

Our goal is to demonstrate the feasibility of laying uncomplicated ultrasound-guided central subclavian catheter by supraclavicular route in the newborn.

NCT ID: NCT02789683 Completed - Metabolic Diseases Clinical Trials

Effects of Emulsification and Lipid Droplet Size on Postprandial Metabolic Responses

Start date: July 2015
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effects of emulsification and lipid droplet size on gastric emptying rate, and to determine if the change in gastric emptying rate can in turn influence postprandial glycemic, insulinemic and lipidemic responses.

NCT ID: NCT02782221 Completed - Metabolic Diseases Clinical Trials

Lipolytic Effects of GH in Human Subjects in Vivo

Start date: May 30, 2016
Phase: N/A
Study type: Interventional

Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways. In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively. Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.

NCT ID: NCT02782208 Completed - Insulin Resistance Clinical Trials

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

Start date: February 10, 2016
Phase: N/A
Study type: Interventional

Growth hormone (GH) is essential for longitudinal bone growth and somatic development. These protein anabolic effects require sufficient nutritional supply. During fasting and caloric restriction GH predominantly promotes fat metabolism. GH counteracts the effect of insulin in many tissues, of which insulin-stimulated glucose uptake in skeletal muscle has been most extensively studied. Substrate competition between elevated free fatty acids and glucose is suggested as a mechanism, and this hypothesis can be tested mechanistically by means of acipimox, which is a nicotinic acid that suppresses the fat metabolizing effects of GH. The hypothesis is, that the suppressive effect of GH on insulin-stimulated glucose uptake in skeletal muscle is obviated by acipimox-induced inhibition of fat metabolism. In order to investigate this, eight adult hypopituitary patients with documented GH-deficiency will be studied in the presence and absence of GH and acipimox, respectively, and biopsies from skeletal muscle and subcutaneous adipose tissue will be analyzed. Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.

NCT ID: NCT02779452 Completed - Clinical trials for Glucose Metabolism Disorders

Gestational Diabetes Mellitus and Neurodevelopment in Newborns

Start date: December 2013
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the feasibility of using a quantitative EEG method to evaluate neurodevelopment in newborns and to evaluate whether subtle neurodevelopmental deficits can be detected in newborns from mothers with gestational diabetes mellitus (GDM) compared to control newborns. The second purpose of this study is to determine whether cord blood concentration in docosahexaenoic acid (DHA), an omega-3 fatty acid, is similar in neonates of well-controlled mothers with gestational diabetes mellitus (GDM) compared to control mothers, and to evaluate whether this contributes to neonates neurodevelopment status.

NCT ID: NCT02778490 Completed - Morbid Obesity Clinical Trials

Effects of Sleeve Gastrectomy on Calcium Metabolism and the Skeleton

Start date: June 15, 2016
Phase:
Study type: Observational

In this pre-post observational study, the investigators will enroll and follow a cohort of about 50 adults undergoing sleeve gastrectomy surgery for weight loss. Pre-operatively and at 6 and 12 months post-operatively, the investigators will use state-of-the-art metabolic and imaging techniques to evaluate calcium metabolism and skeletal health. Specific outcomes include intestinal calcium absorption capacity, bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), and bone structure assessed by QCT and high-resolution peripheral QCT (HR-pQCT).